Inactivated subvirion H7N9 vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Influenza A Virus, H7N9 Subtype

Phase 1

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

CompletedNCT02151344

National Institute of Allergy and Infectious Diseases (NIAID)Influenza A Virus, H7N9 Subtype

Start: 2014-05-31End: 2015-02-28Updated: 2015-03-30

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

CompletedNCT02274545

National Institute of Allergy and Infectious Diseases (NIAID)Influenza A Virus, H7N9 Subtype

Start: 2014-10-31Target: 24Updated: 2017-04-19

Related Papers

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

The Journal of Infectious Diseases2015-12-0953 citations